Search

Your search keyword '"Tsuburaya A"' showing total 42 results
Start Over Author "Tsuburaya A" Journal gastric cancer
42 results on '"Tsuburaya A"'

5. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial

Author

Nishikawa, Kazuhiro, Tsuburaya, Akira, Yoshikawa, Takaki, Takahashi, Masazumi, Tanabe, Kazuaki, Yamaguchi, Kensei, Yoshino, Shigefumi, Namikawa, Tsutomu, Aoyama, Toru, Rino, Yasushi, Kawada, Junji, Tsuji, Akihito, Taira, Koichi, Kimura, Yutaka, Kodera, Yasuhiro, Hirashima, Yoshinori, Yabusaki, Hiroshi, Hirabayashi, Naoki, Fujitani, Kazumasa, Miyashita, Yumi, Morita, Satoshi, and Sakamoto, Junichi

Published
2018
Full Text
View/download PDF

9. High false-negative proportion of intraoperative histological examination as a serious problem for clinical application of sentinel node biopsy for early gastric cancer: final results of the Japan Clinical Oncology Group multicenter trial JCOG0302

Author

Miyashiro, Isao, Hiratsuka, Masahiro, Sasako, Mitsuru, Sano, Takeshi, Mizusawa, Junki, Nakamura, Kenichi, Nashimoto, Atsushi, Tsuburaya, Akira, Fukushima, Norimasa, and The Gastric Cancer Surgical Study Group (GCSSG) in the Japan Clinical Oncology Group (JCOG)

Published
2014
Full Text
View/download PDF

14. Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis

Author

Shitara, Kohei, Morita, Satoshi, Fujitani, Kazumasa, Kadowaki, Shigenori, Takiguchi, Nobuhiro, Hirabayashi, Naoki, Takahashi, Masazumi, Takagi, Masakazu, Tokunaga, Yukihiko, Fukushima, Ryoji, Munakata, Yasuhiro, Nishikawa, Kazuhiro, Takagane, Akinori, Tanaka, Takaho, Sekishita, Yoshiaki, Sakamoto, Junichi, and Tsuburaya, Akira

Published
2012
Full Text
View/download PDF

30. Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer

Author

Nishikawa, Kazuhiro, primary, Koizumi, Wasaburo, additional, Tsuburaya, Akira, additional, Yamanaka, Takeharu, additional, Morita, Satoshi, additional, Fujitani, Kazumasa, additional, Akamaru, Yusuke, additional, Shimada, Ken, additional, Hosaka, Hisashi, additional, Nakayama, Norisuke, additional, Tsujinaka, Toshimasa, additional, and Sakamoto, Junichi, additional

Published
2019
Full Text
View/download PDF

31. Unusual survival for more than 2 years with peritoneal metastases of gastric cancer

Author

Hisahiko Motohashi, Haruhiko Cho, Kazuo Konishi, Akira Tsuburaya, Masahiro Kanari, Osamu Kobayashi, Takaki Yoshikawa, and Motonori Sairenji

Subjects
Male, Antimetabolites, Antineoplastic, Cancer Research, medicine.medical_specialty, Pyridines, Gastroenterology, Drug Administration Schedule, Carcinoembryonic antigen, Gastrectomy, Stomach Neoplasms, Internal medicine, Ascites, medicine, Humans, Survivors, Peritoneal Neoplasms, Aged, Tegafur, Barium enema, biology, business.industry, Cancer, General Medicine, Greater omentum, medicine.disease, Abdominal mass, Surgery, Drug Combinations, Oxonic Acid, medicine.anatomical_structure, Oncology, biology.protein, medicine.symptom, business, Progressive disease, Abdominal surgery
Abstract

We report a patient with peritoneal metastases who was successfully treated with a novel oral fluoropyrimidine anticancer drug, TS-1, as first-line chemotherapy. The patient was a 72-year-old man who had undergone curative resection for type 4 gastric cancer with peritoneal dissemination that was located only at the greater omentum. Final findings were P1, T4, N1, and stage IV. Eighteen months after the gastrectomy, his cancer recurred with peritoneal metastases; these were diagnosed by the presence of multiple stenoses of the colon, an abdominal mass, and elevated levels of the serum tumor markers, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9. He was treated with 100 mg/day of TS-1, given orally, for 28 days, followed by 14 days' rest, as one course. Two courses of the treatment resulted in a marked reduction of the abdominal tumor, without severe toxicity. After 3 courses, barium enema revealed dramatic improvement in the stenoses. Laparoscopy after 11 courses showed neither peritoneal dissemination, nor ascites, and peritoneal lavage cytology was negative. The serum tumor markers were reduced to almost normal levels. Two years after the onset of the peritoneal metastases, the patient is alive without any sign of progressive disease. Our report is the first to demonstrate the advantages of TS-1 as chemotherapy for the treatment of peritoneal metastasis of gastric cancer.

Published
2002
Full Text
View/download PDF

32. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study

Author

Fuse, Nozomu, primary, Bando, Hideaki, additional, Chin, Keisho, additional, Ito, Seiji, additional, Yoshikawa, Takaki, additional, Tsuburaya, Akira, additional, Terashima, Masanori, additional, Kawashima, Yoshiyuki, additional, Fukunaga, Tetsu, additional, Gotoh, Masahiro, additional, Emi, Yasunori, additional, Yoshida, Kazuhiro, additional, Oki, Eiji, additional, Takahashi, Seiji, additional, Kuriki, Hiroshi, additional, Sato, Kumi, additional, and Sasako, Mitsuru, additional

Published
2016
Full Text
View/download PDF

34. Laparoscopic esophagojejunostomy using the EndoStitch and a circular stapler under a direct view created by the ENDOCAMELEON

Author

Yoshikawa, Takaki, primary, Hayashi, Tsutomu, additional, Aoyama, Toru, additional, Cho, Haruhiko, additional, Fujikawa, Hirohito, additional, Shirai, Junya, additional, Hasegawa, Shinichi, additional, Yamada, Takanobu, additional, Oshima, Takashi, additional, Yukawa, Norio, additional, Rino, Yasushi, additional, Masuda, Munetaka, additional, Ogata, Takashi, additional, and Tsuburaya, Akira, additional

Published
2012
Full Text
View/download PDF

36. A prospective feasibility and safety study of laparoscopy-assisted distal gastrectomy for clinical stage I gastric cancer initiated by surgeons with much experience of open gastrectomy and laparoscopic surgery

Author

Yoshikawa, Takaki, primary, Cho, Haruhiko, additional, Rino, Yasushi, additional, Yamamoto, Yuji, additional, Kimura, Masayuki, additional, Fukunaga, Tetsu, additional, Hasegawa, Shinichi, additional, Yamada, Takanobu, additional, Aoyama, Toru, additional, and Tsuburaya, Akira, additional

Published
2012
Full Text
View/download PDF

37. Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis

Author

Shitara, Kohei, primary, Morita, Satoshi, additional, Fujitani, Kazumasa, additional, Kadowaki, Shigenori, additional, Takiguchi, Nobuhiro, additional, Hirabayashi, Naoki, additional, Takahashi, Masazumi, additional, Takagi, Masakazu, additional, Tokunaga, Yukihiko, additional, Fukushima, Ryoji, additional, Munakata, Yasuhiro, additional, Nishikawa, Kazuhiro, additional, Takagane, Akinori, additional, Tanaka, Takaho, additional, Sekishita, Yoshiaki, additional, Sakamoto, Junichi, additional, and Tsuburaya, Akira, additional

Published
2011
Full Text
View/download PDF

42. Advanced gastric carcinoma successfully treated with TS-1 as neoadjuvant chemotherapy.

Author

Yoshikawa, Takaki, Kanari, Masahiro, Tsuburaya, Akira, Kobayashi, Osamu, Sairenji, Motonori, Motohashi, Hisahiko, Kameda, Yoichi, and Noguchi, Yoshikazu

Abstract

We report a patient with advanced gastric carcinoma successfully treated with the novel oral fluoropyrimidine anticancer drug TS-1 as neoadjuvant chemotherapy. The patient was a 76-year-old man who had gastric cancer clinically diagnosed as N2T4, invading the pancreas, the duodenum, and the transverse colon. He was treated as an outpatient with TS-1, 120 mg, administered orally every day for 28 days, followed by 14 days' rest, as one course. Two courses resulted in a marked reduction of the tumor without severe toxicity. Subsequently, the patient underwent curative surgery consisting of distal gastrectomy with D2 lymph node dissection. No surgical complications were observed. On microscopic examination, a few tumor cells were detected in the ulcer scar of the resected stomach and in the regional lymph nodes. Our report is the first to demonstrate the advantages of TS-1 as neoadjuvant chemotherapy for the treatment of advanced gastric carcinoma. [ABSTRACT FROM AUTHOR]

Published
2000
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results